Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.75M | $12.1M | $21.2M | $24.6M | $43.3M | $4.52M | $1.02M | $71.5M | $92.1M | $109M |
| Revenue growth | — | 56.5% | 74.9% | 16.0% | 76.1% | -89.6% | -77.3% | 6877.8% | 28.8% | 18.8% |
| Gross profit | $4.34M | $5.95M | $12.2M | $15.4M | $24.1M | $35.6M | $39.0M | $42.9M | $59.4M | $73.6M |
| Gross margin | 56.0% | 49.1% | 57.6% | 62.8% | 55.7% | 789.0% | 3801.6% | 60.0% | 64.5% | 67.3% |
| Operating income | -$1.58M | -$2.13M | $180K | -$3.69M | -$2.14M | $361K | -$12.3M | -$26.4M | -$13.7M | $11.7M |
| Operating margin | -20.4% | -17.6% | 0.8% | -15.0% | -4.9% | 8.0% | -1199.1% | -36.9% | -14.9% | 10.7% |
| Net income | -$1.54M | -$2.10M | $226K | -$3.14M | -$2.21M | $378K | -$11.4M | -$17.6M | -$20.1M | $5.13M |
| Net margin | -19.9% | -17.3% | 1.1% | -12.8% | -5.1% | 8.4% | -1115.9% | -24.6% | -21.8% | 4.7% |
| EPS (diluted) | -$0.05 | -$0.21 | $0.02 | -$0.23 | -$0.15 | $0.02 | -$0.64 | -$1.03 | -$1.10 | $0.27 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$466K | -$1.48M | $793K | -$1.66M | -$6.31M | $726K | $10.7M | -$7.24M | $4.89M | $18.7M |
| Capital expenditures | $178K | $42.2K | $34.4K | $87.7K | $68.0K | $100K | $81.0K | $87.0K | $112K | $58.0K |
| Free cash flow | -$644K | -$1.52M | $758K | -$1.75M | -$6.38M | $626K | $10.6M | -$7.33M | $4.78M | $18.7M |
| Share buybacks | $807K | $390K | — | — | — | — | $20.0M | $7.52M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.03M | $5.12M | $8.91M | $18.9M | $10.5M | $84.7M | $18.2M | $13.9M | $13.4M | $23.4M |
| Total assets | $11.5M | $9.76M | $25.1M | $56.6M | $60.3M | $141M | $135M | $183M | $171M | $177M |
| Total liabilities | — | $3.54M | $6.60M | $11.8M | $10.4M | $9.61M | $8.54M | $56.8M | $54.2M | $48.6M |
| Long-term debt | — | — | — | — | — | — | — | $34.2M | $30.8M | $21.4M |
| Shareholders' equity | $7.81M | $6.22M | $18.5M | $44.9M | $50.0M | $131M | $126M | $127M | $117M | $128M |
| Retained earnings | -$28.3M | -$30.4M | -$30.3M | -$33.4M | -$35.6M | -$35.3M | -$46.7M | -$64.3M | -$84.4M | -$79.2M |
| Shares (wtd avg diluted) | 29.7M | 9.82M | 11.9M | 13.4M | 14.8M | 17.7M | 17.8M | 17.1M | 18.3M | 19.0M |
Every figure is extracted from OptimizeRx Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.